Global Semaglutide API Market Insights, Forecast to 2028

Market Analysis and Insights: Global Semaglutide API Market
Due to the COVID-19 pandemic, the global Semaglutide API market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Oral Grade accounting for % of the Semaglutide API global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Semaglutide Tablets segment is altered to an % CAGR throughout this forecast period.
China Semaglutide API market size is valued at US$ million in 2021, while the US and Europe Semaglutide API are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Semaglutide API landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Semaglutide API include Bachem, AmbioPharm, Rochem International, Dr. Reddy's Laboratories, Teva, Anthem Biosciences, Zabcbio, Viruj Pharmaceutical and ZPC Peptide. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
In terms of production side, this report researches the Semaglutide API capacity, production, growth rate, market share by manufacturers and by region (region level and country level), from 2017 to 2022, and forecast to 2028.
In terms of sales side, this report focuses on the sales of Semaglutide API by region (region level and country level), by company, by Type and by Application. from 2017 to 2022 and forecast to 2028.
Global Semaglutide API Scope and Segment
Semaglutide API market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Semaglutide API market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on production capacity, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Oral Grade
Injection Grade
Segment by Application
Semaglutide Tablets
Semaglutide Injection
By Company
Bachem
AmbioPharm
Rochem International
Dr. Reddy's Laboratories
Teva
Anthem Biosciences
Zabcbio
Viruj Pharmaceutical
ZPC Peptide
Production by Region
North America
Europe
China
Japan
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE